Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.11
WBA's Cash-to-Debt is ranked lower than
80% of the 373 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.55 vs. WBA: 0.11 )
Ranked among companies with meaningful Cash-to-Debt only.
WBA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.2 Max: No Debt
Current: 0.11
0.03
No Debt
Equity-to-Asset 0.39
WBA's Equity-to-Asset is ranked lower than
53% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.41 vs. WBA: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
WBA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.55 Max: 0.64
Current: 0.39
0.39
0.64
Debt-to-Equity 0.57
WBA's Debt-to-Equity is ranked higher than
51% of the 292 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.55 vs. WBA: 0.57 )
Ranked among companies with meaningful Debt-to-Equity only.
WBA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.16 Max: 0.7
Current: 0.57
0
0.7
Debt-to-EBITDA 2.10
WBA's Debt-to-EBITDA is ranked higher than
55% of the 291 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.18 vs. WBA: 2.10 )
Ranked among companies with meaningful Debt-to-EBITDA only.
WBA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.33  Med: 0.98 Max: 2.48
Current: 2.1
0.33
2.48
Interest Coverage 8.90
WBA's Interest Coverage is ranked lower than
70% of the 326 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.97 vs. WBA: 8.90 )
Ranked among companies with meaningful Interest Coverage only.
WBA' s Interest Coverage Range Over the Past 10 Years
Min: 7.2  Med: 31.03 Max: 312.82
Current: 8.9
7.2
312.82
Piotroski F-Score: 5
Altman Z-Score: 3.48
Beneish M-Score: -2.32
WACC vs ROIC
6.80%
11.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 4.65
WBA's Operating Margin % is ranked higher than
67% of the 375 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. WBA: 4.65 )
Ranked among companies with meaningful Operating Margin % only.
WBA' s Operating Margin % Range Over the Past 10 Years
Min: 4.21  Med: 5.02 Max: 5.83
Current: 4.65
4.21
5.83
Net Margin % 3.33
WBA's Net Margin % is ranked higher than
65% of the 375 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.97 vs. WBA: 3.33 )
Ranked among companies with meaningful Net Margin % only.
WBA' s Net Margin % Range Over the Past 10 Years
Min: 2.53  Med: 3.49 Max: 4.08
Current: 3.33
2.53
4.08
ROE % 14.62
WBA's ROE % is ranked higher than
67% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.14 vs. WBA: 14.62 )
Ranked among companies with meaningful ROE % only.
WBA' s ROE % Range Over the Past 10 Years
Min: 9.67  Med: 14.38 Max: 18.56
Current: 14.62
9.67
18.56
ROA % 5.90
WBA's ROA % is ranked higher than
66% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.77 vs. WBA: 5.90 )
Ranked among companies with meaningful ROA % only.
WBA' s ROA % Range Over the Past 10 Years
Min: 5.31  Med: 7.68 Max: 10.34
Current: 5.9
5.31
10.34
ROC (Joel Greenblatt) % 42.13
WBA's ROC (Joel Greenblatt) % is ranked higher than
84% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.33 vs. WBA: 42.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.31  Med: 26.97 Max: 39.02
Current: 42.13
24.31
39.02
3-Year Revenue Growth Rate 11.50
WBA's 3-Year Revenue Growth Rate is ranked higher than
80% of the 343 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.70 vs. WBA: 11.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WBA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.5  Med: 12.5 Max: 16.5
Current: 11.5
0.5
16.5
3-Year EBITDA Growth Rate 9.00
WBA's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 312 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.50 vs. WBA: 9.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WBA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.2  Med: 12.6 Max: 17.5
Current: 9
-2.2
17.5
3-Year EPS without NRI Growth Rate 23.60
WBA's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 288 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.30 vs. WBA: 23.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WBA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.1  Med: 14.1 Max: 23.6
Current: 23.6
-12.1
23.6
GuruFocus has detected 2 Warning Signs with Walgreens Boots Alliance Inc WBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WBA's 30-Y Financials

Financials (Next Earnings Date: 2018-06-29)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

WBA Guru Trades in Q1 2017

Lee Ainslie 1,013,553 sh (New)
Steven Cohen 327,100 sh (New)
Ray Dalio 20,187 sh (New)
Andreas Halvorsen 12,063,404 sh (+52.70%)
Paul Tudor Jones 38,334 sh (+11.71%)
Mairs and Power 14,364 sh (+10.11%)
Pioneer Investments 186,947 sh (+2.16%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Larry Robbins Sold Out
Mario Gabelli 444,614 sh (-1.28%)
Dodge & Cox 7,569 sh (-6.31%)
Ken Fisher 7,155 sh (-8.40%)
Leon Cooperman 826,103 sh (-11.56%)
Joel Greenblatt 330,643 sh (-51.94%)
Jim Simons 23,100 sh (-98.80%)
» More
Q2 2017

WBA Guru Trades in Q2 2017

John Hussman 50,000 sh (New)
Larry Robbins 1,747,858 sh (New)
John Buckingham 12,237 sh (New)
Ray Dalio 62,547 sh (+209.84%)
Jim Simons 51,300 sh (+122.08%)
Paul Tudor Jones 68,703 sh (+79.22%)
Joel Greenblatt 566,818 sh (+71.43%)
Mairs and Power 15,916 sh (+10.80%)
Mario Gabelli 464,409 sh (+4.45%)
Tom Gayner 2,135,000 sh (unchged)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Dodge & Cox 7,569 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Ken Fisher 7,134 sh (-0.29%)
Pioneer Investments 169,248 sh (-9.47%)
Andreas Halvorsen 3,012,489 sh (-75.03%)
Lee Ainslie 251,710 sh (-75.17%)
» More
Q3 2017

WBA Guru Trades in Q3 2017

Robert Olstein 49,000 sh (New)
George Soros 85,600 sh (New)
Caxton Associates 8,300 sh (New)
Jim Simons 1,226,610 sh (+2291.05%)
Ray Dalio 110,893 sh (+77.30%)
John Buckingham 14,393 sh (+17.62%)
Ken Fisher 7,655 sh (+7.30%)
Mario Gabelli 468,040 sh (+0.78%)
Tom Gayner 2,135,000 sh (unchged)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Pioneer Investments 169,248 sh (unchged)
Dodge & Cox 7,569 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Lee Ainslie Sold Out
Joel Greenblatt 548,622 sh (-3.21%)
Mairs and Power 15,164 sh (-4.72%)
John Hussman 25,000 sh (-50.00%)
Paul Tudor Jones 16,386 sh (-76.15%)
Andreas Halvorsen 485,000 sh (-83.90%)
Larry Robbins 49,400 sh (-97.17%)
» More
Q4 2017

WBA Guru Trades in Q4 2017

First Pacific Advisors 6,400 sh (New)
David Dreman 6,324 sh (New)
Tom Russo 125 sh (New)
Larry Robbins 6,829,696 sh (+13725.30%)
Pioneer Investments 1,650,553 sh (+875.23%)
Ray Dalio 393,897 sh (+255.20%)
Robert Olstein 144,000 sh (+193.88%)
Paul Tudor Jones 37,586 sh (+129.38%)
John Buckingham 27,874 sh (+93.66%)
Caxton Associates 14,637 sh (+76.35%)
Ken Fisher 9,315 sh (+21.69%)
Joel Greenblatt 614,058 sh (+11.93%)
John Hussman 25,000 sh (unchged)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Andreas Halvorsen Sold Out
Mario Gabelli 455,652 sh (-2.65%)
Mairs and Power 14,564 sh (-3.96%)
Dodge & Cox 5,669 sh (-25.10%)
George Soros 42,600 sh (-50.23%)
Jim Simons 36,800 sh (-97.00%)
» More
» Details

Insider Trades

Latest Guru Trades with WBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-12-31 Add 11.93%0.07%$64.48 - $76.95 $ 63.92-9%614,058
Mario Gabelli 2017-12-31 Reduce -2.65%0.01%$64.48 - $76.95 $ 63.92-9%455,652
Robert Olstein 2017-12-31 Add 193.88%0.88%$64.48 - $76.95 $ 63.92-9%144,000
George Soros 2017-12-31 Reduce -50.23%0.1%$64.48 - $76.95 $ 63.92-9%42,600
Ken Fisher 2017-12-31 Add 21.69%$64.48 - $76.95 $ 63.92-9%9,315
David Dreman 2017-12-31 New Buy0.26%$64.48 - $76.95 $ 63.92-9%6,324
Dodge & Cox 2017-12-31 Reduce -25.10%$64.48 - $76.95 $ 63.92-9%5,669
Joel Greenblatt 2017-09-30 Reduce -3.21%0.02%$77.16 - $82.74 $ 63.92-20%548,622
Mario Gabelli 2017-09-30 Add 0.78%$77.16 - $82.74 $ 63.92-20%468,040
George Soros 2017-09-30 New Buy0.2%$77.16 - $82.74 $ 63.92-20%85,600
Robert Olstein 2017-09-30 New Buy0.49%$77.16 - $82.74 $ 63.92-20%49,000
Ken Fisher 2017-09-30 Add 7.30%$77.16 - $82.74 $ 63.92-20%7,655
Joel Greenblatt 2017-06-30 Add 71.43%0.26%$76.34 - $86.54 $ 63.92-22%566,818
Mario Gabelli 2017-06-30 Add 4.45%0.01%$76.34 - $86.54 $ 63.92-22%464,409
Ken Fisher 2017-06-30 Reduce -0.29%$76.34 - $86.54 $ 63.92-22%7,134
Leon Cooperman 2017-06-30 Sold Out 2.76%$76.34 - $86.54 $ 63.92-22%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare:BSP:RADL3, TSE:3391, TSE:9989, SHSE:600998, TSE:3141, TSE:3088, TSE:3349, SSE:2928, JSE:CLS, TSE:7649, TSX:PJC.A, SHSE:603939, SHSE:603883, JSE:DCP, TSE:9627, SZSE:002727, TSE:3549, TSE:3098, NYSE:RAD, TSE:3148 » details
Traded in other countries:WBA.Austria, W8A.Germany, WBA.Mexico, WBA.Switzerland, 0R0C.UK,
Headquarter Location:USA
Walgreens Boots Alliance Inc is a pharmacy led health and wellbeing company. It operates retail pharmacy store chain in the United States. The firm sells and markets its products under brands such as Walgreens, Duane Reade, Boots and Alliance Healthcare.

Walgreens is one of the nation's largest retail pharmacies, with about 8,100 drugstores throughout the United States. The firm recently acquired half of Rite Aid's locations, which will push its store count to approximately 10,000. This large network of stores enables the firm to reach a significant portion of the U.S. population, providing excellent brand recognition. Prescription drugs account for about two thirds of sales, with the balance attributable to front-store products such as grocery, health, and beauty items.

Top Ranked Articles about Walgreens Boots Alliance Inc

The Good Shepherd Investor We feel we serve as a shepherd of our concentrated stock portfolio and of our end clients and shareholders
David was the king of Israel and the writer of many of the Psalms. He spent his formative years as a shepherd and framed his life’s work around the key concepts from his profession. Herds were the primary form of wealth back then, while common stocks are a primary form today. We feel we serve as a shepherd of our concentrated stock portfolio and of our end clients and shareholders. As we get ready for the next phase in the U.S. stock market, we thought it would be helpful to compare what we do with what David did as a good shepherd. Read more...
Detailed Research: Economic Perspectives on General Dynamics, Garmin, Walgreens Boots Alliance, The Home Depot, Facebook, and Apple — What Drives Growth in Today's Competitive Landscape
52-Week Company Lows Details the 52-week lows of the following companies: Procter & Gamble, General Electric, US Bancorp, Kraft Heinz, Walgreens Boots Alliance and American International Group
According to GuruFocus’ list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...
Thinking about buying stock in Amazon.com, CBS, Lowes, Nike and Walgreens Boots Alliance?
Thinking about buying stock in BlackBerry Ltd, Cognizant Technology Solutions, Netflix, Twitter or Walgreens Boots Alliance?
Walgreens Boots Alliance Stock Down Before Fiscal Q2 Earnings Report Walgreens reversed earlier gains ahead of its earnings report
Walgreen Boots Alliance (NASDAQ:WBA) stock is down 1.5% at closing on Tuesday after rallying over 1.5% on Monday, March 27. The company is slated to release its fiscal second-quarter earnings on March 28. Read more...
Boosted by Earnings Beat, Walgreens Shares Rise Drugstore chain raises full-year guidance
Pharmacy retailer Walgreens Boots Alliance Inc. (NASDAQ:WBA) reported strong second-quarter 2018 earnings before the opening bell on Wednesday, sending shares higher. Read more...
Stocks That Fell to 3-Year Lows in the Week of March 23 General Electric Co. (GE), Walgreens Boots Alliance Inc. (WBA), Dominion Energy Inc. (D), and Southern Co. (SO) have declined to their respective three-year lows.
General Electric Co. (NYSE:GE), Walgreens Boots Alliance Inc. (NASDAQ:WBA), Dominion Energy Inc. (NYSE:D), and Southern Co. (NYSE:SO) have declined to their three-year lows. Read more...
Express Scripts and Walgreens Boots Alliance Expand Group Purchasing Efforts to Include Specialty Brand Medications
Minority Report It is our opinion that today’s well-known fact is tied to the faith the stock market has in the ability of technology companies to continue their amazing momentum

Ratios

vs
industry
vs
history
PE Ratio 17.66
WBA's PE Ratio is ranked lower than
52% of the 303 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.85 vs. WBA: 17.66 )
Ranked among companies with meaningful PE Ratio only.
WBA' s PE Ratio Range Over the Past 10 Years
Min: 10.2  Med: 19.09 Max: 35.8
Current: 17.66
10.2
35.8
Forward PE Ratio 10.86
WBA's Forward PE Ratio is ranked higher than
81% of the 74 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.83 vs. WBA: 10.86 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.66
WBA's PE Ratio without NRI is ranked lower than
51% of the 303 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.28 vs. WBA: 17.66 )
Ranked among companies with meaningful PE Ratio without NRI only.
WBA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.2  Med: 19.09 Max: 35.8
Current: 17.66
10.2
35.8
PB Ratio 2.34
WBA's PB Ratio is ranked lower than
66% of the 363 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.73 vs. WBA: 2.34 )
Ranked among companies with meaningful PB Ratio only.
WBA' s PB Ratio Range Over the Past 10 Years
Min: 1.6  Med: 2.7 Max: 4.22
Current: 2.34
1.6
4.22
PS Ratio 0.54
WBA's PS Ratio is ranked lower than
57% of the 367 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. WBA: 0.54 )
Ranked among companies with meaningful PS Ratio only.
WBA' s PS Ratio Range Over the Past 10 Years
Min: 0.36  Med: 0.63 Max: 1.08
Current: 0.54
0.36
1.08
Price-to-Free-Cash-Flow 11.67
WBA's Price-to-Free-Cash-Flow is ranked higher than
71% of the 151 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.33 vs. WBA: 11.67 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WBA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.87  Med: 15.99 Max: 103.55
Current: 11.67
9.87
103.55
Price-to-Operating-Cash-Flow 9.39
WBA's Price-to-Operating-Cash-Flow is ranked higher than
53% of the 196 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.41 vs. WBA: 9.39 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WBA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.43  Med: 11.02 Max: 20.71
Current: 9.39
6.43
20.71
EV-to-EBIT 13.53
WBA's EV-to-EBIT is ranked higher than
50% of the 318 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.28 vs. WBA: 13.53 )
Ranked among companies with meaningful EV-to-EBIT only.
WBA' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 13.6 Max: 29
Current: 13.53
6.8
29
EV-to-EBITDA 10.49
WBA's EV-to-EBITDA is ranked higher than
51% of the 325 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.83 vs. WBA: 10.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
WBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.3  Med: 10.3 Max: 20.9
Current: 10.49
5.3
20.9
EV-to-Revenue 0.64
WBA's EV-to-Revenue is ranked lower than
57% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.58 vs. WBA: 0.64 )
Ranked among companies with meaningful EV-to-Revenue only.
WBA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.7 Max: 1.3
Current: 0.64
0.4
1.3
PEG Ratio 3.80
WBA's PEG Ratio is ranked lower than
67% of the 177 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.19 vs. WBA: 3.80 )
Ranked among companies with meaningful PEG Ratio only.
WBA' s PEG Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.99 Max: 15.67
Current: 3.8
0.5
15.67
Shiller PE Ratio 21.12
WBA's Shiller PE Ratio is ranked lower than
57% of the 99 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.51 vs. WBA: 21.12 )
Ranked among companies with meaningful Shiller PE Ratio only.
WBA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.95  Med: 24.05 Max: 36.91
Current: 21.12
13.95
36.91
Current Ratio 0.90
WBA's Current Ratio is ranked lower than
68% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.20 vs. WBA: 0.90 )
Ranked among companies with meaningful Current Ratio only.
WBA' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.66 Max: 2.36
Current: 0.9
0.9
2.36
Quick Ratio 0.45
WBA's Quick Ratio is ranked lower than
72% of the 351 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.77 vs. WBA: 0.45 )
Ranked among companies with meaningful Quick Ratio only.
WBA' s Quick Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.51 Max: 1.7
Current: 0.45
0.27
1.7
Days Inventory 36.56
WBA's Days Inventory is ranked higher than
52% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.43 vs. WBA: 36.56 )
Ranked among companies with meaningful Days Inventory only.
WBA' s Days Inventory Range Over the Past 10 Years
Min: 35.11  Med: 51.49 Max: 60.44
Current: 36.56
35.11
60.44
Days Sales Outstanding 21.43
WBA's Days Sales Outstanding is ranked lower than
56% of the 278 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.58 vs. WBA: 21.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
WBA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.04  Med: 14.88 Max: 24.17
Current: 21.43
11.04
24.17
Days Payable 51.59
WBA's Days Payable is ranked higher than
59% of the 264 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 45.06 vs. WBA: 51.59 )
Ranked among companies with meaningful Days Payable only.
WBA' s Days Payable Range Over the Past 10 Years
Min: 28.73  Med: 34.47 Max: 51.59
Current: 51.59
28.73
51.59

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.46
WBA's Dividend Yield % is ranked higher than
61% of the 497 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.93 vs. WBA: 2.46 )
Ranked among companies with meaningful Dividend Yield % only.
WBA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.68  Med: 1.75 Max: 3.11
Current: 2.46
0.68
3.11
Dividend Payout Ratio 0.39
WBA's Dividend Payout Ratio is ranked higher than
71% of the 294 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.32 vs. WBA: 0.39 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WBA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.18  Med: 0.36 Max: 0.64
Current: 0.39
0.18
0.64
3-Year Dividend Growth Rate 5.90
WBA's 3-Year Dividend Growth Rate is ranked lower than
57% of the 190 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.70 vs. WBA: 5.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WBA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.8  Med: 13.6 Max: 26
Current: 5.9
3.8
26
Forward Dividend Yield % 2.50
WBA's Forward Dividend Yield % is ranked higher than
54% of the 470 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.22 vs. WBA: 2.50 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.84
WBA's 5-Year Yield-on-Cost % is ranked higher than
62% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.97 vs. WBA: 3.84 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WBA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.07  Med: 2.75 Max: 4.9
Current: 3.84
1.07
4.9
3-Year Average Share Buyback Ratio -2.50
WBA's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 214 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.50 vs. WBA: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WBA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.9  Med: 0 Max: 3.5
Current: -2.5
-4.9
3.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.77
WBA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
72% of the 212 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.56 vs. WBA: 0.77 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WBA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.74  Med: 2.52 Max: 18.64
Current: 0.77
0.74
18.64
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.47
WBA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
62% of the 58 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.39 vs. WBA: 1.47 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
WBA' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.55  Med: 1.29 Max: 2.92
Current: 1.47
0.55
2.92
Price-to-Median-PS-Value 0.84
WBA's Price-to-Median-PS-Value is ranked higher than
61% of the 312 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. WBA: 0.84 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WBA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.15 Max: 3.29
Current: 0.84
0.57
3.29
Price-to-Peter-Lynch-Fair-Value 2.75
WBA's Price-to-Peter-Lynch-Fair-Value is ranked lower than
81% of the 110 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.73 vs. WBA: 2.75 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WBA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.96 Max: 6.3
Current: 2.75
0.57
6.3
Earnings Yield (Greenblatt) % 7.38
WBA's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.71 vs. WBA: 7.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 7.3 Max: 14.7
Current: 7.38
3.4
14.7
Forward Rate of Return (Yacktman) % 15.81
WBA's Forward Rate of Return (Yacktman) % is ranked higher than
62% of the 255 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.05 vs. WBA: 15.81 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WBA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 5.1  Med: 13.5 Max: 23
Current: 15.81
5.1
23

More Statistics

Revenue (TTM) (Mil) $124,028.00
EPS (TTM) $ 3.62
Beta0.79
Volatility22.95%
52-Week Range $61.74 - 87.79
Shares Outstanding (Mil)991.67

Analyst Estimate

Aug18 Aug19 Aug20
Revenue (Mil $) 130,662 138,138 141,965
EBIT (Mil $) 7,462 7,989
EBITDA (Mil $) 9,301 9,908
EPS ($) 5.60 6.08 6.67
EPS without NRI ($) 5.60 6.08 6.67
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.71%
Dividends per Share ($) 1.62 1.70

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}